Browsing by Author "Attoye T"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Multi-stakeholder consensus on a target product profile for an HIV cure.
    (2021-Jan) Lewin SR; Attoye T; Bansbach C; Doehle B; Dubé K; Dybul M; SenGupta D; Jiang A; Johnston R; Lamplough R; McCune JM; Nabel GJ; Ndung'u T; Pottage J; Ripin D; Rooney JF; Sikazwe I; Nsubuga M; Warren M; Deeks SG; HIV Frontiers, Global Health Innovative Technology Solutions, The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Joint Adherent Brothers & Sisters against AIDS, Kampala, Uganda.; University North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.; ViiV Healthcare, Brentford, UK.; Sanofi Global Research and Development, Cambridge, MA, USA.; AVAC, New York, NY, USA.; amfAR, The Foundation for AIDS Research, New York City, NY, USA.; The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, VIC, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia. Electronic address: sharon.lewin@unimelb.edu.au.; Bill & Melinda Gates Foundation, Seattle, WA, USA.; McKinsey & Company Secondee at The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Department of Global Health, University of Washington, The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Gilead Sciences, Foster City, CA, USA.; Clinton Health Access Initiative, Boston, MA, USA.; Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Max Planck Institute for Infection Biology, Berlin, Germany; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; Division of Infection and Immunity, University College London, London, UK.; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA.; International AIDS Society, Geneva, Switzerland.; University of California, San Francisco, CA, USA.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy. An intervention that successfully cured a reasonable fraction of adults would be sufficient to advance to the clinic. These target product profiles will require further discussion and ongoing revisions as the field matures.
  • Thumbnail Image
    Item
    The case for an HIV cure and how to get there.
    (2021-Jan) Dybul M; Attoye T; Baptiste S; Cherutich P; Dabis F; Deeks SG; Dieffenbach C; Doehle B; Goodenow MM; Jiang A; Kemps D; Lewin SR; Lumpkin MM; Mathae L; McCune JM; Ndung'u T; Nsubuga M; Peay HL; Pottage J; Warren M; Sikazwe I; Global Health Division, The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.; Agence Nationale de Recherches sur le SIDA et les Hepatites Virales, Paris, France.; RTI International, Research Triangle Park, NC, USA.; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.; Viiv Healthcare, Brentford, UK.; International Treatment Preparedness Coalition, Johannesburg, South Africa.; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA. Electronic address: mrd54@georgetown.edu.; Sommartel, London, UK.; Africa Health Research Institute, Durban, South Africa; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban South Africa; Max Planck Institute for Infection Biology, Berlin, Germany; University College London, London, UK.; AIDS Vaccine Advocacy Coalition, New York, NY, USA.; McKinsey & Company Secondee at The Bill & Melinda Gates Foundation, Seattle, WA, USA.; Joint Adherent Brothers & Sisters Against AIDS, Kampala, Uganda.; Kenya Ministry of Health, Nairobi, Kenya.; University of California, San Francisco, California, USA.; Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.; Center for Global Health Practice and Impact, Georgetown University, Washington, DC, USA.; Office of AIDS Research, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.; CIDRZ; Centre for Infectious Disease Research in Zambia (CIDRZ)
    In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.